Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
Open Access
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotinClinical Case Reports, 2019
- Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulationJournal of Molecular Modeling, 2017
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group StudyJournal of Clinical Oncology, 2017
- Targeting ALK: Precision Medicine Takes on Drug ResistanceCancer Discovery, 2017
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung CancerCancer Discovery, 2016
- Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphomaJournal of Cancer Research and Clinical Oncology, 2014
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper MutantCancer Cell, 2011
- Anaplastic large cell lymphoma: pathological, molecular and clinical featuresBritish Journal of Haematology, 2001
- ALK-positive lymphoma: a single disease with a broad spectrum of morphology.1998
- ALK-Positive Lymphoma: A Single Disease With a Broad Spectrum of MorphologyBlood, 1998